-
Mashup Score: 0EMJ Cardiology 11.1 2023 - 7 month(s) ago
Explore a unique selection of peer-reviewed articles, exclusive interviews with leading experts, and a comprehensive review of the ESC Congress…
Source: www.emjreviews.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
What are the latest updates on treating tricuspid regurgitation? We spoke with a leading researcher at ESC Congress 2023 to find out.
Source: cardiovascularbusiness.comCategories: Cardiologists, Latest HeadlinesTweet-
New insights to risk evaluation, TriScore in #EHJ by Julien Dreyfus and data on #tricuspid regurgitation treatment at and after #ESC2023 with @vonBardelebenRS https://t.co/cH5Kj21CA0
-
-
Mashup Score: 0ESC 2023 – Heart Failure Guideline Review - 8 month(s) ago
In this short video series, recorded at ESC 2023 in Amsterdam, Prof Carolyn Lam (National Heart Centre Singapore, SG) and Prof Giuseppe Rosano (St George’s University Medical
Source: www.radcliffecardiology.comCategories: Latest Headlines, Partners & KOLsTweet-
📽️ #ESC2023 #HeartFailure #GuidelineReview with @lamcardio and @GMCRosano 🩺Latest updates 🧑⚕️Clinical impacts 🫀Future management strategies Watch Now➡️ https://t.co/FgjJXBDrn5 Supported by an unrestricted educational grant from AstraZeneca. https://t.co/OJWVP6r0UX
-
-
Mashup Score: 0Dr. Ross Campbell: Using AI to Diagnose Heart Failure - 8 month(s) ago
Artificial intelligence (AI)-based analysis of echocardiograms has the potential to significantly reduce clinical time and expedite heart failure diagnosis wait times, according to results from the OPERA-AI study, a collab orative analysis conducted by the University of Glasgow, AstraZeneca, NHS Greater Glasgow and Clyde, and Golden Jubilee University National Hospital. In this interview, DocWire News spoke with Dr. Ross Campbell, of the University of Glasgow, who presented the OPERA findings at the
Source: www.docwirenews.comCategories: Latest Headlines, Partners & KOLsTweet-
Dr. Ross Campbell, of the University of Glasgow, talks about the OPERA-AI study, which showed that #artificialintelligence has the potential to enhance #heartfailure detection. #ESCCongress #ESC2023 https://t.co/MyUNeIMwOL https://t.co/d1hjwapiUX
-
-
Mashup Score: 4
Guidelines in Practice assesses new and updated guidance published in 2023 by the European Society of Cardiology at its annual congress
Source: www.medscape.co.ukCategories: General Medicine News, Latest HeadlinesTweet-
ESC 2023 Guidelines Reflect Treatment Advances and New Trial Findings ➡️ https://t.co/whZYLR0oEk #ESC2023 #HeartFailure #Diabetes https://t.co/38ouX5fOsD
-
-
Mashup Score: 0
The final day of the European Society of Cardiology 2023 Congress featured a joint session with JAMA Cardiology, “Achieving Global Health Equity: A New Challenge in Heart Failure.”
Source: www.ajmc.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
The final day of the European Society of Cardiology 2023 Congress featured a joint session with JAMA Cardiology, “Achieving Global Health Equity: A New Challenge in Heart Failure.” Learn more: https://t.co/LbKfdVjKFa #ESC2023 https://t.co/lnENmnkHAV
-
-
Mashup Score: 4ESC 2023 – Heart Failure Guideline Review - 8 month(s) ago
In this short video series, recorded at ESC 2023 in Amsterdam, Prof Carolyn Lam (National Heart Centre Singapore, SG) and Prof Giuseppe Rosano (St George’s University Medical
Source: www.radcliffecardiology.comCategories: Latest Headlines, Partners & KOLsTweet-
Explore the latest #ESC2023 #HeartFailure #GuidelineUpdates with @lamcardio and @GMCRosano. Discover key recommendations and clinical insights for the future of HF management. ➡️ https://t.co/uYjxkmPPOF Supported by an unrestricted educational grant from AstraZeneca. https://t.co/h8H7GwSoQs
-
-
Mashup Score: 0Atrial Fibrillation Ablation Improves Outcomes in Patients with End-stage Heart Failure - 8 month(s) ago
August 31, 2023 — Atrial fibrillation ablation is associated with lower rates of death, urgent heart transplantation or left ventricular assist device (LVAD) implantation compared with medical therapy in patients with end-stage heart failure, according to late breaking research presented in a Hot Line session today at ESC Congress 2023.1 Patients with end-stage heart failure eligible for heart transplantation have been excluded from major trials, leaving them with no recommendations or evidence for the optimal treatment of atrial fibrillation and advanced heart failure. There is uncertainty around the application of guidelines in this group2,3 and many novel advances in heart failure therapy are withheld in clinical practice. The CASTLE-HTx trial tested whether atrial fibrillation ablation is superior to medical therapy concerning mortality and need for urgent transplantation or LVAD implantation.4 The trial was conducted at the Heart and Diabetes Center North Rhine-Westphalia (NRW)
Source: www.dicardiology.comCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor @escardio #Atrialfibrillation #ablation is associated with lower rates of death, urgent #hearttransplantation, left ventricular assist device implantation compared with #medicaltherapy in patients with end-stage #heartfailure: https://t.co/BfnDLf6AnS #ESC23 #esc2023
-
-
Mashup Score: 0BIOMAG-I Study OCT Analysis Confirmed That BIOTRONIK’s Newest Resorbable Magnesium Scaffold Resorbed at 12 Months - 8 month(s) ago
September 5, 2023 — New data from the BIOMAG-I first-in-human trial shed light on the vascular healing process following the implantation of DREAMS 3G, BIOTRONIK’s third-generation resorbable magnesium scaffold (RMS). A detailed intravascular optical coherence tomography (OCT) analysis demonstrated that 99.3% of the struts completely degraded at one year.1Dr. Masaru Seguchi from the German Heart Centre in Munich, Germany presented the findings at the European Society of Cardiology’s (ESC) congress in Amsterdam. While earlier BIOMAG-I study results provided favorable outcomes with regards to late lumen loss at six and 12 months,2,3 the additional analysis assessed the 12-months vessel healing profile. The analysis included patients from the multicenter BIOMAG-I trial who underwent OCT imaging pre- and post-procedure, at six and 12 months. One year after implantation of DREAMS 3G RMS, the strut degradation rate was 99.3% as measured by OCT. “We aimed to investigate the scaffold’s resorpt
Source: www.dicardiology.comCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor @BIOTRONIK_US @escardio New data from the #BIOMAG-I first-in-human trial shed light on the vascular healing process following the implantation of #DREAMS_3G, BIOTRONIK’s third-generation resorbable magnesium scaffold (#RMS): https://t.co/wLDQeAGv1E #ESC23 #esc2023
-
-
Mashup Score: 0ESC 2023 Highlights - Cardiology Update - 8 month(s) ago
Dr. Chadi Alraies discusses the top highlights from the European Society of Cardiology Congress 2023 in Amsterdam from August 25 to 28, 2023.
Source: www.cardiology-update.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ESC Congress 2023 Highlights 👉https://t.co/mZ13EUHNlk #ESCCongress #ESC2023 #cardiotwitter @chadialraies @cpgale3 @YndigegnY @gbiondizoccai @drjohnm @HeartOTXHeartMD @mirvatalasnag @AnastasiaSMihai @torresviera @SABOURETCardio @lamelaspablo @Almanfi_Cardio @georgedangas @djc795 https://t.co/WY15f6g8DP
-
New open access cardiology journal, available now! https://t.co/iSUCbDDueq Explore peer-reviewed articles, expert interviews, and ESC Congress 2023 highlights in the latest EMJ Cardiology issue! #ESC2023 #Cardiologists #Heartfailure #Cardiovasculardisease https://t.co/03YdOJBzX6